Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors

Endocrine-Related Cancer

Volumn 18, Issue 6, 2011, Pages 759-771

  Chen, Zhihong ^a   Forman, Lora W ^a   Miller, Kenneth A ^b   English, Brandon ^b   Takashima, Asami ^a   Bohacek, Regine A ^c   Williams, Robert M ^b   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Boston De Novo Design   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSE DEHYDROGENASE; LENTIVIRUS VECTOR; PROTEIN KINASE C DELTA; RAS PROTEIN; SHORT HAIRPIN RNA;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CLONOGENIC ASSAY; CYTOTOXICITY TEST; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; MOLECULAR DOCKING; NEUROENDOCRINE TUMOR; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL;

ACETOPHENONES; ANIMALS; APOPTOSIS; BENZOPYRANS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; NEUROENDOCRINE TUMORS; NIH 3T3 CELLS; PROTEIN KINASE C-DELTA;

EID: 84862961434     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0224     Document Type: Article

References (51)

1. Arber N, Neugut AI, Weinstein IB & Holt P 1997 Molecular genetics of small bowel cancer. Cancer Epidemiology, Biomarkers & Prevention 6 745-748. (Pubitemid 27427631)
2. Arnold R, Simon B & Wied M 2000 Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62 (Suppl 1) 84-91. (doi:10.1159/000051861)
3. Arnold R, Wied M & Behr TH 2002 Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opinion on Pharmacotherapy 3 643-656. (doi:10.1517/14656566.3.6.643)
4. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, Cascon A, Harenberg T, Schiavi F, Pawlu C et al. 2007 Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. Journal of Clinical Endocrinology and Metabolism 92 2784-2792. (doi:10.1210/jc.2006-2833)
5. Brown JM, Schwanke CM, Pershouse MA, Pfau JC & Holian A 2005 Effects of rottlerin on silica-exacerbated systemic autoimmune disease in New Zealand mixed mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 289 L990-L998. (doi:10.1152/ajplung.00078.2005)
6. Chen CY & Faller DV 1995 Direction of p21(ras)-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 11 1487-1498.
7. Chen CY & Faller DV 1996 Phosphorylation of Bcl-2 protein and association with p21(Ras) in Ras-induced apoptosis. Journal of Biological Chemistry 271 2376-2379. (doi:10.1074/jbc.271.5.2376)
8. Chen CY & Faller DV 1999 Selective inhibition of protein kinase C isozymes by Fas ligation. Journal of Biological Chemistry 274 15320-15328. (doi:10.1074/jbc.274.22.15320)
9. Chen CY, Forman LW & Faller DV 1996 Calcium-dependent immediate-early gene induction in lymphocytes is negatively regulated by p21(Ha-ras). Molecular and Cellular Biology 16 6582-6592. (Pubitemid 26361017)
10. Chen CY, Liou J, Forman LW & Faller DV 1998a Correlation of genetic instability and apoptosis in the presence of oncogenic Ki-Ras. Cell Death and Differentiation 5 984-995. (doi:10.1038/sj.cdd.4400448)
11. Chen CY, Liou J, Forman LW & Faller DV 1998b Differential regulation of discrete apoptotic pathways by Ras. Journal of Biological Chemistry 273 16700-16709. (doi:10.1074/jbc.273.27.16700)
12. Chen CY, Juo P, Liou J, Yu Q, Blenis J & Faller DV 2001 Activation of FADD and caspase 8 in Ras-mediated apoptosis. Cell Growth and Differentiation 12 297-306.
13. Chung DC, Brown SB, Graeme-Cook F, Seto M, Warshaw AL, Jensen RT & Arnold A 2000 Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. Journal of Clinical Endocrinology and Metabolism 85 4373-4378. (doi:10.1210/jc.85.11.4373)
14. Downward J 2003 Targeting RAS signalling pathways in cancer therapy. Nature Reviews. Cancer 3 11-22. (doi:10.1038/nrc969)
15. Evers BM, Rady PL, Tyring SK, Sanchez RL, Rajaraman S, Townsend CM Jr & Thompson JC 1992 Amplification of the HER-2/neu protooncogene in human endocrine tumors. Surgery 112 211-217.
16. Faller DV, Mundschau LJ, Forman LW & Quinones MA 1994 v-mos suppresses platelet-derived growth factor (PDGF) type-β receptor autophosphorylation and inhibits PDGF-BB-mediated signal transduction. Journal of Biological Chemistry 269 5022-5029.
17. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C & Arnold R 1999 Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. American Journal of Gastroenterology 94 1381-1387. (doi:10.1111/j.1572-0241.1999.01090.x)
18. Frasch SC, Henson PM, Kailey JM, Richter DA, Janes MS, Fadok VA & Bratton DL 2000 Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. Journal of Biological Chemistry 275 23065-23073. (doi:10.1074/jbc.M003116200)
19. Fryer RM, Hsu AK, Wang Y, Henry M, Eells J & Gross GJ 2002 PKC-delta inhibition does not block preconditioning-induced preservation in mitochondrial ATP synthesis and infarct size reduction in rats. Basic Research in Cardiology 97 47-54. (doi:10.1007/s395-002-8387-x)
20. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G & Marks F 1994 Rottlerin, a novel protein kinase inhibitor. Biochemical and Biophysical Research Communications 199 93-98. (doi:10.1006/bbrc.1994.1199)
21. Guda K, Natale L & Markowitz SD 2007 An improved method for staining cell colonies in clonogenic assays. Cytotechnology 54 85-88. (doi:10.1007/s10616-007-9083-2)
22. Guo SS, Wu X, Shimoide AT, Wong J, Moatamed F & Sawicki MP 2003 Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. Journal of Endocrinology 179 73-79. (doi:10.1677/joe.0.1790073)
23. Karhoff D, Sauer S, Schrader J, Arnold R, Fendrich V, Bartsch DK & Horsch D 2007 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 85 45-53. (doi:10.1159/000100508)
24. Kawahara M, Kammori M, Kanauchi H, Noguchi C, Kuramoto S, Kaminishi M, Endo H & Takubo K 2002 Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. European Journal of Surgical Oncology 28 140-146. (doi:10.1053/ejso.2001.1229)
25. Keenan C, Goode N & Pears C 1997 Isoform specificity of activators and inhibitors of protein kinase C gamma and delta. FEBS Letters 415 101-108. (doi:10.1016/S0014-5793(97)01104-6)
26. Kikkawa U, Matsuzaki H & Yamamoto T 2002 Protein kinase C delta (PKC delta): activation mechanisms and functions. Journal of Biochemistry 132 831-839. (Pubitemid 36090647)
27. Kunnimalaiyaan M & Chen H 2006 The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17 139-142. (doi:10.1097/00001813-200602000-00004)
28. Leotlela PD, Jauch A, Holtgreve-Grez H & Thakker RV 2003 Genetics of neuroendocrine and carcinoid tumours. Endocrine-Related Cancer 10 437-450. (doi:10.1677/erc.0.0100437)
29. Li GZ, Eller MS, Hanna K & Gilchrest BA 2004 Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. Experimental Cell Research 301 189-200. (doi:10.1016/j.yexcr.2004.08.019)
30. Liedke M, Karnbach C, Kalinin V, Herbst B, Frilling A & Broelsch CE 1998 Detection of H-ras and K-ras in tumors of gastrointestinal-pancreatic system. Langenbecks Archiv für Chirurgie 115 255-259.
31. Liou JS, Chen CY, Chen JS & Faller DV 2000 Oncogenic Ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species. Journal of Biological Chemistry 275 39001-39011. (doi:10.1074/jbc.M007154200)
32. Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. Journal of Cellular Physiology 198 277-294. (doi:10.1002/jcp.10409)
33. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR & Rashid A 2005 Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Modern Pathology 18 1632-1640. (doi:10.1038/modpathol.3800490)
34. Ma P, Magut M, Chen X & Chen CY 2002 P53 is necessary for the apoptotic response mediated by a transient increase of Ras activity. Molecular and Cellular Biology 22 2928-2938. (doi:10.1128/MCB.22.9.2928-2938.2002)
35. Maitra A, Krueger JE, Tascilar M, Offerhaus GJ, Angeles-Angeles A, Klimstra DS, Hruban RH & Albores-Saavedra J 2000 Carcinoid tumors of the extrahepatic bile ducts: a study of seven cases. American Journal of Surgical Pathology 24 1501-1510. (doi:10.1097/00000478-200011000-00005)
36. Oberg K 1999 Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Annals of Oncology 10 (Suppl 2) S3-S8. (doi:10.1023/A:1027336026601)
37. Oberg K 2001 Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Annals ofOncology 12 (Suppl 2) S111-S114. (doi:10.1023/A:1012465801251)
38. Parekh D, Ishizuka J, Townsend CM Jr, Haber B, Beauchamp RD, Karp G, Kim SW, Rajaraman S, Greeley G Jr & Thompson JC 1994 Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 9 83-90. (doi:10.1097/00006676-199401000-00013)
39. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU & Komminoth P 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocrine-Related Cancer 11 855-860. (doi:10.1677/erc.1.00841)
40. Rake JB, Quinones MA & Faller DV 1991 Inhibition of platelet-derived growth factor-mediated signal transduction by transforming ras. Suppression of receptor autophosphorylation. Journal of Biological Chemistry 266 5348-5352. (Pubitemid 21909497)
41. Schuller HM, Falzon M, Gazdar AF & Hegedus T 1987 Cell type-specific differences in metabolic activation of N-nitrosodiethylamine by human lung cancer cell lines. IARC Scientific Publications 84 138-140.
42. Serrano M, Lin AW, McCurrach ME, Beach D & Lowe SW 1997 Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell 88 593-602. (doi:10.1016/S0092-8674(00)81902-9)
43. Stancu M, Wu TT, Wallace C, Houlihan PS, Hamilton SR & Rashid A 2003 Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. Modern Pathology 16 1189-1198. (doi:10.1097/01.MP.0000097362.10330.B1)
44. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R & Horsch D 2005 BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. American Journal of Clinical Pathology 123 256-260. (doi:10.1309/YQBR9C05RU4DD3RN)
45. Van Buren G, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F, Camp ER, Yao JC et al. 2007 The development and characterization of a human midgut carcinoid cell line. Clinical Cancer Research 13 4704-4712. (doi:10.1158/1078-0432.CCR-06-2723)
46. Wang L, Ignat A & Axiotis CA 2002 Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Applied Immunohistochemistry & Molecular Morphology 10 139-146. (doi:10.1097/00022744-200206000-00008)
47. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR & Rashid A 2005 Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Modern Pathology 18 1079-1087. (doi:10.1038/modpathol.3800389)
48. Xia S, Forman LW & Faller DV 2007 Protein kinase C{delta} is required for survival of cells expressing activated p21RAS. Journal of Biological Chemistry 282 13199-13210. (doi:10.1074/jbc.M610225200)
49. Rasprotein requires PDK1. Cellular Signalling 21 502-508. (doi:10.1016/j.cellsig.2008.12.002)
50. Zhang D, Anantharam V, Kanthasamy A & Kanthasamy AG 2007 Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 322 913-922. (doi:10.1124/jpet.107.124669)
51. Zikusoka MN, Kidd M, Eick G, Latich I & Modlin IM 2005 The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104 2292-2309. (doi:10.1002/cncr.21451)